Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy

被引:14
作者
Song, Yuan [1 ,2 ,3 ]
Liu, Yonghao [1 ,2 ,3 ]
Teo, Huey Yee [1 ,2 ,3 ]
Liu, Haiyan [1 ,2 ,3 ]
机构
[1] Natl Univ Singapore, Life Sci Inst, Immunol Programme, Singapore, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Immunol Translat Res Program, Singapore, Singapore
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore
基金
新加坡国家研究基金会;
关键词
gamma delta T cell; cytokine; cancer; immunotherapy; cellular therapy; ZOLEDRONIC ACID; HEPATOCELLULAR-CARCINOMA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECEPTOR; BLADDER-CANCER; B-CELLS; PHASE-I; RECOGNITION; TUMOR; DIFFERENTIATION;
D O I
10.3389/fimmu.2022.914839
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
gamma delta T cells represent a small percentage of T cells in circulation but are found in large numbers in certain organs. They are considered to be innate immune cells that can exert cytotoxic functions on target cells without MHC restriction. Moreover, gamma delta T cells contribute to adaptive immune response via regulating other immune cells. Under the influence of cytokines, gamma delta T cells can be polarized to different subsets in the tumor microenvironment. In this review, we aimed to summarize the current understanding of antigen recognition by gamma delta T cells, and the immune regulation mediated by gamma delta T cells in the tumor microenvironment. More importantly, we depicted the polarization and plasticity of gamma delta T cells in the presence of different cytokines and their combinations, which provided the basis for gamma delta T cell-based cancer immunotherapy targeting cytokine signals.
引用
收藏
页数:13
相关论文
共 160 条
[1]   Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma [J].
Abe, Yu ;
Muto, Masato ;
Nieda, Mie ;
Nakagawa, Yasunori ;
Nicol, Andrew ;
Kaneko, Touru ;
Goto, Shigenori ;
Yokokawa, Kiyoshi ;
Suzuki, Kenshi .
EXPERIMENTAL HEMATOLOGY, 2009, 37 (08) :956-968
[2]   Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer [J].
Aoki, Taku ;
Viatsushita, Hirokazu ;
Hoshikawa, Mayumi ;
Hasegawa, Kiyoshi ;
Kokudo, Norihiro ;
Kakimi, Kazuhiro .
CYTOTHERAPY, 2017, 19 (04) :473-485
[3]   Interleukin 2: from immunostimulation to immunoregulation and back again [J].
Bachmann, Martin F. ;
Oxenius, Annette .
EMBO REPORTS, 2007, 8 (12) :1142-1148
[4]   IL-21 enhances the potential of human γδ T cells to provide B-cell help [J].
Bansal, Raj R. ;
Mackay, Charles R. ;
Moser, Bernhard ;
Eberl, Matthias .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (01) :110-119
[5]   IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population [J].
Barjon, Clement ;
Michaud, Henri-Alexandre ;
Fages, Angeline ;
Dejou, Cecile ;
Zampieri, Alexandre ;
They, Laetitia ;
Gennetier, Aurelie ;
Sanchez, Francoise ;
Gros, Laurent ;
Eliaou, Jean-Francois ;
Bonnefoy, Nathalie ;
Lafont, Virginie .
ONCOIMMUNOLOGY, 2018, 7 (01)
[6]   Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments [J].
Barros, Rafael Di Marco ;
Roberts, Natalie A. ;
Dart, Robin J. ;
Vantourout, Pierre ;
Jandke, Anett ;
Nussbaumer, Oliver ;
Deban, Livija ;
Cipolat, Sara ;
Hart, Rosie ;
Iannitto, Maria Luisa ;
Laing, Adam ;
Spencer-Dene, Bradley ;
East, Philip ;
Gibbons, Deena ;
Irving, Peter M. ;
Pereira, Pablo ;
Steinhoff, Ulrich ;
Hayday, Adrian .
CELL, 2016, 167 (01) :203-+
[7]   TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer [J].
Beatson, Richard E. ;
Parente-Pereira, Ana C. ;
Halim, Leena ;
Cozzetto, Domenico ;
Hull, Caroline ;
Whilding, Lynsey M. ;
Martinez, Olivier ;
Taylor, Chelsea A. ;
Obajdin, Jana ;
Hoang, Kim Ngan Luu ;
Draper, Benjamin ;
Iqbal, Ayesha ;
Hardiman, Tom ;
Zabinski, Tomasz ;
Man, Francis ;
de Rosales, Rafael T. M. ;
Xie, Jinger ;
Aswad, Fred ;
Achkova, Daniela ;
Joseph, Chung-Yang Ricardo ;
Ciprut, Sara ;
Adami, Antonella ;
Roider, Helge G. ;
Hess-Stumpp, Holger ;
Gyorffy, Balazs ;
Quist, Jelmar ;
Grigoriadis, Anita ;
Sommer, Anette ;
Tutt, Andrew N. J. ;
Davies, David M. ;
Maher, John .
CELL REPORTS MEDICINE, 2021, 2 (12)
[8]   Immune Escape Mechanisms as a Guide for Cancer Immunotherapy [J].
Beatty, Gregory L. ;
Gladney, Whitney L. .
CLINICAL CANCER RESEARCH, 2015, 21 (04) :687-692
[9]   Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].
Bennouna, Jaafar ;
Bompas, Emmanuelle ;
Neidhardt, Eve Marie ;
Rolland, Frederic ;
Philip, Irene ;
Galea, Celine ;
Salot, Samuel ;
Saiagh, Soraya ;
Audrain, Marie ;
Rimbert, Marie ;
Micheaux, Sylvie Lafaye-de ;
Tiollier, Jerome ;
Negrier, Sylvie .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) :1599-1609
[10]   Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors [J].
Bennouna, Jaafar ;
Levy, Vincent ;
Sicard, Helene ;
Senellart, Helene ;
Audrain, Marie ;
Hiret, Sandrine ;
Rolland, Frederic ;
Bruzzoni-Giovanelli, Heriberto ;
Rimbert, Marie ;
Galea, Celine ;
Tiollier, Jerome ;
Calvo, Fabien .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (10) :1521-1530